6HHF

Crystal Structure of AKT1 in Complex with Covalent-Allosteric AKT Inhibitor Borussertib


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.9 Å
  • R-Value Free: 0.274 
  • R-Value Work: 0.231 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib inKRAS-Mutant Pancreatic and Colorectal Cancer.

Weisner, J.Landel, I.Reintjes, C.Uhlenbrock, N.Trajkovic-Arsic, M.Dienstbier, N.Hardick, J.Ladigan, S.Lindemann, M.Smith, S.Quambusch, L.Scheinpflug, R.Depta, L.Gontla, R.Unger, A.Muller, H.Baumann, M.Schultz-Fademrecht, C.Gunther, G.Maghnouj, A.Muller, M.P.Pohl, M.Teschendorf, C.Wolters, H.Viebahn, R.Tannapfel, A.Uhl, W.Hengstler, J.G.Hahn, S.A.Siveke, J.T.Rauh, D.

(2019) Cancer Res. 79: 2367-2378

  • DOI: 10.1158/0008-5472.CAN-18-2861

  • PubMed Abstract: 
  • Aberrations within the PI3K/AKT signaling axis are frequently observed in numerous cancer types, highlighting the relevance of these pathways in cancer physiology and pathology. However, therapeutic interventions employing AKT inhibitors often suffer ...

    Aberrations within the PI3K/AKT signaling axis are frequently observed in numerous cancer types, highlighting the relevance of these pathways in cancer physiology and pathology. However, therapeutic interventions employing AKT inhibitors often suffer from limitations associated with target selectivity, efficacy, or dose-limiting effects. Here we present the first crystal structure of autoinhibited AKT1 in complex with the covalent-allosteric inhibitor borussertib, providing critical insights into the structural basis of AKT1 inhibition by this unique class of compounds. Comprehensive biological and preclinical evaluation of borussertib in cancer-related model systems demonstrated a strong antiproliferative activity in cancer cell lines harboring genetic alterations within the PTEN, PI3K, and RAS signaling pathways. Furthermore, borussertib displayed antitumor activity in combination with the MEK inhibitor trametinib in patient-derived xenograft models of mutant KRAS pancreatic and colon cancer. SIGNIFICANCE: Borussertib, a first-in-class covalent-allosteric AKT inhibitor, displays antitumor activity in combination with the MEK inhibitor trametinib in patient-derived xenograft models and provides a starting point for further pharmacokinetic/dynamic optimization.


    Organizational Affiliation

    Faculty of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, Germany.,Department of Visceral and General Surgery, St. Josef Hospital, Ruhr-University Bochum, Germany.,Department of Visceral and General Surgery, St. Josefs-Hospital, Dortmund, Germany.,Faculty of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, Germany. daniel.rauh@tu-dortmund.de stephan.hahn@rub.de jens.siveke@uk-essen.de.,Department of Internal Medicine, Ruhr-University Bochum, Knappschaftskrankenhaus, Bochum, Germany.,Department of Surgery, Ruhr-University Bochum, Knappschaftskrankenhaus, Bochum, Germany.,Department of Molecular Gastrointestinal Oncology, Ruhr-University Bochum, Bochum, Germany. daniel.rauh@tu-dortmund.de stephan.hahn@rub.de jens.siveke@uk-essen.de.,Department of Internal Medicine, St. Josefs-Hospital, Dortmund, Germany.,German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany. daniel.rauh@tu-dortmund.de stephan.hahn@rub.de jens.siveke@uk-essen.de.,Drug Discovery Hub Dortmund (DDHD) am Zentrum für Integrierte Wirkstoffforschung (ZIW), Dortmund, Germany.,Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK), partner site Essen, West German Cancer Center, University Hospital Essen, Essen, Germany.,German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.,Department of Molecular Gastrointestinal Oncology, Ruhr-University Bochum, Bochum, Germany.,Institute of Pathology, Ruhr-University of Bochum, Bochum, Germany.,Lead Discovery Center GmbH, Dortmund, Germany.,Leibniz Research Centre for Working Environment and Human Factors (IfADo), TU Dortmund University, Dortmund, Germany.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
RAC-alpha serine/threonine-protein kinase
A
446Homo sapiensMutation(s): 3 
Gene Names: AKT1 (PKB, RAC)
EC: 2.7.11.1
Find proteins for P31749 (Homo sapiens)
Go to Gene View: AKT1
Go to UniProtKB:  P31749
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
G4K
Query on G4K

Download SDF File 
Download CCD File 
A
Borussertib
C36 H34 N6 O3
NFXSQFADJLOQHR-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.9 Å
  • R-Value Free: 0.274 
  • R-Value Work: 0.231 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 64.370α = 90.00
b = 68.440β = 90.00
c = 102.510γ = 90.00
Software Package:
Software NamePurpose
XDSdata reduction
XSCALEdata scaling
PHASERphasing
PHENIXrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
German Federal Ministry for Education and ResearchGermanyBMBF 01GS08104
German Federal Ministry for Education and ResearchGermany01ZX1303C

Revision History 

  • Version 1.0: 2019-03-20
    Type: Initial release
  • Version 1.1: 2019-05-15
    Type: Data collection, Database references